flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.
News from flanders.bio and its members
Oxurion NV announces full enrollment in its Phase 1 trial evaluating the safety of its plasma kallikrein inhibitor THR-149 for treatment of DME, ahead of schedule
Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces today that it has completed enrollment of its Phase 1 study of THR-149, a novel plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME). A total of 15 patient have been recruited. The study enrolled faster than anticipated and initial data will be released by early Q3 2019.
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
Galapagos NV (Euronext & NASDAQ: GLPG), MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) and Novartis Pharma AG (SIX: NOVN-CH) announced today the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
Vlaanderen investeert in gepersonaliseerde geneeskunde
Vlaams minister van Innovatie Philippe Muyters wil de Vlaamse farmaceutische, medische en de sector van de bio-, nano- en medische technologie aanzetten om de omwenteling van de gepersonaliseerde geneeskunde niet te missen. Het potentieel is groot, zowel voor de patiënten als de sector zelf. Voor goede projecten ligt er in totaal 10 miljoen euro klaar.
Biocartis Group NV: Biocartis Announces Global Collaboration with Covance
Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the global strategic commercialization agreement with Covance, LabCorp's Drug Development business. The agreement aims at offering the Idylla(TM) platform and its existing Idylla(TM) oncology assay menu to Covance's customer base. Several Idylla(TM) instruments have already been placed at Covance sites in the US and China to support global oncology trials. The agreement provides for additional placement of Idylla(TM) instruments at Covance sites globally to support customer needs for clinical trials and, when appropriate, to validate and implement companion diagnostic applications.